B-LCL-CDG2 Cells
€800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | B-LCL-CDG2 is an EBV-transformed B lymphocyte cell line derived from a young girl suffering from PMM2-CDG. PMM2-CDG is a rare inborn error of metabolism, which results in defective synthesis of glycosylated oligosaccharide chains of many tissue and blood glycoproteins and/or glycosphingolipids. The primary cause of defective glycosylation is based on mutations in the enzyme phosphomannomutase 2 (PMM2). There are two distinct mutations for the PMM2 gene. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Congenital Disorders of Glycosylation |
| Applications | Genotyping of CDG effects in immune cells, functional testing (e.g. B cell surface antigens), testing of cytotoxic drugs, mutational analysis, analysis of apoptotic mechanisms, HLA-typing, impact of defective glycosylation of distinct cellular glycoproteins on diverse functions. |
Characteristics
| Age | Child |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Round cells |
| Cell type | B lymphocyte |
| Growth properties | Suspension, Cluster |
Regulatory Data
| Citation | B-LCL-CDG2 (Cytion catalog number 302013) |
|---|---|
| Biosafety level | 2 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_A9Y1 |
Biomolecular Data
| Surface antigens | CD60a- (GD3), CD60c-(7-O-acetylated GD3), CD75s+ sialylated lactosaminyl Noligosaccharides), CD77- (Gb3, globotriaosylceramide) |
|---|---|
| Antigen expression | CD10-, CD19+, CD20+, CD21+, CD22+, CD23+, CD24+, CD37+m CD38+, CD39+, CD40+, CD53+, CD71+, CD72(+), CD73+, CD74 (+), CD80+, CD81+, CD82+, CD83-, CD84-, CD85+, CD86+, MHC class I+, MHC class II+ |
| Viruses | Transformant: EBV |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 105 cells/ml and keep the cell concentration within the range of 1 x 105 to 5 x 105 cells/ml for optimal growth. |
| Fluid renewal | Once the medium colour turned into yellow |
| Post-Thaw Recovery | Medium |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Material Transfer Agreement
If you intend to use Cytion cell lines solely for internal research at a single research site, please complete and sign our Material Transfer Agreement (MTA) and submit it along with your order.
For any commercial applications - including but not limited to fee-for-service work, quality control testing, product release, diagnostic use, or regulatory studies - please complete the Intended Use Form so we can prepare a suitable agreement tailored to your project.
Please note: The MTA applies only to certain cell lines. If this notice and the MTA document appear on a product page, the agreement is applicable. For cell lines not covered by the MTA, no reference to the agreement will be shown. The MTA is not valid for customers in the Americas, China, or Taiwan. Please contact our U.S. entity to receive the appropriate agreement.